In the present study, we performed ctDNA analysis using targeted next-generation sequencing (NGS) with the cancer personalized profiling by deep sequencing (CAPP-Seq) technology [18,19] on samples prior to and following ALK-TKI treatment to study the genomic composition of ALK-positive NSCLC in a real-world setting. This evidence concerns the gene ALK and cancer.